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New Drug: Prevacid I.V. (Lansoprazole) Injection
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*Updated information on Protonix I.V. may be found at the end of this document.*

What It Is
Prevacid I.V. (lansoprazole) is an intravenous
proton pump inhibitor.1

Indications
When patients are unable to take oral
formulations of lansoprazole, Prevacid I.V. is a
short–term alternative for all grades of erosive
esophagitis. It is intended for administration up to
seven days. Once patients are able to take oral
medications, they should be switched to oral
1
Prevacid for a total of six to eight weeks.

How Supplied

The reconstituted solution must then be further
diluted in 50 mL of either 0.9% Sodium Chloride
Injection USP, 5% Dextrose Injection USP, or
Lactated Ringer’s Injection, USP prior to
administration.1
Solutions in 5% Dextrose Injection, USP must
be used within 12 hours at room temperature,
whereas those in 0.9% Sodium Chloride Injection
USP or Lactated Ringer’s Injection, USP can be
1
used in 24 hours. Refrigeration is not required.
The resulting infusion must be administered
using the in-line filter provided over a 30 minute
period. The filter must be used to remove any
precipitate formed when the reconstituted product
is mixed with intravenous solutions. Filtration
does not alter the amount of lansoprazole
1
available to the patient.

Prevacid I.V. is available as a single-dose vial
containing 30 mg of lansoprazole powder. The
single-dose vial is supplied in a pack containing a
1.2 micron in-line filter which is required for its
administration. It is supplied in a tray of ten
1
packs.
It should be stored at room temperature 25oC
(77oF) [range 15oC to 30oC or 59oF to 86oF] and
1
protected from light.

Manufacturer

Dosage

Commentary

The recommended adult dosage for Prevacid
I.V. for use in erosive esophagitis is 30 mg daily
administered by intravenous infusion over 30
minutes for up to seven days. It is intended only
for patients unable to take oral therapy. Oral
1
therapy should be started as soon as possible.
No dosage adjustment is needed in renal
impairment or in the elderly. Patients with severe
1
hepatic disease may need dosage reduction.

Erosive esophagitis is a serious chronic form
of gastroesophageal reflux disease (GERD). It is
characterized by symptoms of heartburn, acid
regurgitation, and abdominal discomfort.
If
untreated it can cause esophageal mucosal damage
and lead to complications such as stricture,
Acid
hemorrhage, and esophageal cancer.2,3
suppressive therapy is the primary therapy for
GERD.2 Evidence-based medicine supports the
use of proton pump inhibitors over H2-blockers
for severe cases of GERD [Evidence level C,
consensus].2
Prevacid I.V. (lansoprazole) is the second
intravenous proton pump inhibitor to be approved
in the U.S. It is not yet approved in Canada.

Admixture Preparation and Administration
Reconstitute each 30 mg vial with 5 mL of
Sterile Water for Injection, USP. After gentle
mixture, the resultant solution can be kept at room
1
temperature for one hour prior to further dilution.

TAP Pharmaceuticals Inc.
Forest Lake, IL 60045
800-621-1020
www.tap.com
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Protonix I.V. (pantoprazole) was approved in
March 2001 as an alternative to oral therapy for
short-term use in gastroesophageal reflux disease
associated with a history of erosive esophagitis.
The dosage is 40 mg once daily via intravenous
infusion. It was later approved for use in
Zollinger-Ellison syndrome where oral therapy
was not possible. An 80 mg adult dose every 12
hours is recommended for this indication. In
Canada, it is also approved for treatment of nonsteroidal anti-inflammatory drug-induced ulcers.
A 15 minute infusion or a recently approved two
minute infusion is needed.4
Both of these proton pump inhibitors have
similar adverse effects, drug interactions,
contraindications, and precautions. They are both
listed as Pregnancy Category B.
Protonix I.V. is supplied in 40 mg vials that
must be refrigerated at 2 oC to 8oC (36 oF to 46oF).
Once prepared for intravenous administration,
solutions are stable at room temperature for 22
hours.4
The average wholesale cost for Prevacid I.V. is
listed as $26.83 per 30 mg vial whereas Protonix
I.V. costs $29.28 per 40 mg vial.5
Both Prevacid I.V. and Protonix I.V. are
intended for short term therapy in patients who are
unable to take oral proton pump inhibitors.
Protonix I.V. has the additional approved
indication for use in Zollinger-Ellison Syndrome.
Protonix I.V. requires refrigeration whereas
Prevacid I.V. does not. Protonix I.V. has the
advantage of a two minute infusion time and does
not require an in-line filter. In-line filtration was
required for the older formulations of Protonix
I.V. Recently reformulated versions do not.
Prevacid I.V. requires a 30 minute infusion period
and the use of an in-line filter.1,4
There are no comparative clinical studies of
the intravenous efficacy of these two proton pump
inhibitors.
Formulary choices will probably be driven by
group purchasing organization contract prices
because of the similarities of these intravenous
proton pump inhibitors.
*On October 28, 2004, the FDA approved a
supplemental new drug application submitted by
Wyeth Pharmaceuticals for room temperature
storage of Protonix I.V.6 Wyeth will begin
shipment of room temperature storage Protonix

I.V. in the first quarter of 2005. This change
results from formulation changes.
Current
product on shelves and in distribution must still be
refrigerated.
Users of this document are cautioned to use their own
professional judgment and consult any other necessary
or appropriate sources prior to making clinical
judgments based on the content of this document. Our
editors have researched the information with input
from experts, government agencies, and national
organizations. Information and Internet links in this
article were current as of the date of publication.

Levels of Evidence
In accordance with the trend towards Evidence-Based
Medicine, we are citing the LEVEL OF EVIDENCE
for the statements we publish.
Level
A

B

C
D

Definition
High-quality randomized controlled trial (RCT)
High-quality meta-analysis (quantitative
systematic review)
Nonrandomized clinical trial
Nonquantitative systematic review
Lower quality RCT
Clinical cohort study
Case-control study
Historical control
Epidemiologic study
Consensus
Expert opinion
Anecdotal evidence
In vitro or animal study

Adapted from Siwek J, et al. How to write an evidence-based
clinical review article. Am Fam Physician 2002;65:251-8.
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